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Abstract
More people die annually from cardiovascular disease than from any other cause. Two
risk factors for cardiovascular disease are hyperlipidemia and inflammation. Current drugs that
are prescribed to regulate lipid levels often have adverse effects such as liver dysfunction. Bluegreen algae (BGA), also known as cyanobacteria, have been consumed for years for their health
benefits because they are believed to increase energy and prevent disease. One genus of edible
blue-green algae is Spirulina plantesis (SP, Spirulina). Various studies have shown that Spirulina
may have anti-cancer and anti-inflammation and anti-bacterial properties. In a previous study,
Spirulina platensis lowered triglyceride and cholesterol levels in hyperlipidemic rats. The rats
were fed a Spirulina supplemented diet and their lipid levels were measured by their fecal output
and intestinal absorption. However, the study did not involve isolation of the compounds
responsible for this biological activity. The goal of this project is to isolate the specific
compound(s) responsible for the anti-inflammatory and hypolipidemic effects of Spirulina
platensis.

2

Introduction
Cardiovascular disease is the number one cause of death in men and women in the United
States (Ford 2012). Cardiovascular disease is defined as changes in the physiology and structure
of the heart or blood vessels that impairs function (AHA 2015). This research project focused on
two risk factors for cardiovascular disease: hyperlipidemia and inflammation. Inflammation is an
immune system response to harmful stimuli. Hyperlipidemia is an increase in triglycerides in the
blood plasma (Gotto 1977). Hypercholersterolemia is a subset of hyperlipidemia defined as an
increase in total cholesterol levels in the blood (Gotto 1977).
Hypercholesteromlemia can be familial or can be triggered by lifestyle and diet (Haines
2013). The two processes involved in cholesterol regulation are cholesterol synthesis and
cholesterol absorption from the diet. Cholesterol synthesis begins in the mevalonate pathway
(Figure 1). The rate-limiting enzyme in cholesterol biosynthesis is 3-hydroxy-3-methyl-glutarylCoA Reductase (HMG-CoA Reductase or HMGR), the enzyme that converts HMG-CoA into
mevalonate (Haines 2013). Mevalonate is converted to squalene and then to lanosterol. There are
two pathways that convert lanesterol to cholesterol: the Kandutch-Russell pathway and the Bloch
pathway. The Kandutch-Russell pathway converts lanosterol to lathosterol and 7dehydrocholesterol before converting it to cholesterol while desmosterol is the intermediate in
the Bloch pathway (Wu 2014) (Figure 2). The intermediates of cholesterol synthesis are used as
biomarkers to determine the rate of in vivo cholesterol synthesis.
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Figure 1. Enzymes and products of the mevalonate pathway (Haines 2013).

Bloch Pathway

Acetate

HMG
G CoA

Desmosterol

Mevalonate

Cholesterol

Lanosterol

7-

Kan
andutsch-Russell Pathway

Lathosterol

dehydrochole
sterol

Kandutsch-Russell
Russell Pathway (Wu
(
Figure 2. Biosynthesis of cholesterol through the Bloch and Kandutsch
2014).

4

Dietary cholesterol absorption begins in the small intestine. Cholesterol particles form
micelles and pass from the lumen of the intestine into the blood (Elshourbagy 2014). Cholesterol
is insoluble in the plasma and is transported as lipoproteins. The types of lipoproteins in
circulation are high-density lipoproteins (HDL), intermediate density lipoproteins (IDL) lowdensity lipoproteins (LDL) and very low-density lipoproteins (VDL) (Elshourbagy 2014). The
level of density of the lipoproteins represents the amount of protein they carry, with HDL
composed of the highest level of protein (Elshourbagy 2014). HDL and LDL are the most
commonly monitored lipoproteins. HDL and LDL are colloquially referred to as “good
cholesterol” and “bad cholesterol” respectively. HDL facilitates reverse cholesterol transport, the
process in which excess cholesterol from cells is returned to the liver to be degraded
(Elshourbagy 2014). Dyslipidemia is a decrease in the amount of HDL. LDL transports
cholesterol from the liver to peripheral tissues. A buildup of LDL in the plasma leads to
inflammation and atherosclerosis (Elshourbagy 2014).
LDL buildup in blood vessels puts stress on the vessel walls (Salisbury 2014). This stress
damages the vessel walls inducing the inflammatory response. Macrophages and other immune
cells recruited as part of the inflammatory response secrete of pro-inflammatory cytokines such
as tumor necrosis factor alpha (TNFα) and interleukin-1 beta (IL-1β,IL-1B) (Salisbury2014).
These cytokines further progress the inflammatory state. Animal studies have shown that HDL
decreases inflammation by removing LDL from vessel walls (Elshourbagy 2014).
The lipid hypothesis states that high LDL levels correlate positively with cardiovascular
disease risk and high HDL levels correlate negatively (Tobert 2003). In 1984, the National
Institute of Health began to urge physicians to monitor the diets and nutrition of their patients
with hypercholesterolemia in order to control their LDL levels. The first drugs employed to treat
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hypercholesterolemia inhibited enzymes at the end stages of the mevalonate pathway. However,
most of these drugs had adverse side effects such as the development of cataracts and toxicity.
As a result, research shifted to the rate-limiting enzyme in cholesterol synthesis, HMGR. The
first HMGR inhibitor was called compactin. It was isolated from a bacterial broth culture by a
Japanese scientist in the 1970’s. The most common class of HMGR inhibitors is the statin
family. Statins bind competitively to the enzyme’s active site. The first clinically approved statin,
lovastatin, was isolated from a fermented Aspergillus terreus broth (Tobert 2003). Eight
derivatives of lovastatin and compactin have been synthesized (Figure 5). Other treatments for
hypercholesterolemia include fibrates, bile acid sequestrates, and nicotinic acid.
Current treatment of hyperlipidemia focuses on monitoring specific lipid levels and
reducing all cardiovascular disease risk factors. Data derived from clinical trials and
observational studies have led to the development of three health questions recommended by the
American Heart Association to determine therapy options. Rather than basing therapies solely on
LDL levels, treatment intensity is decided based on age, comorbidity, in addition to LDL levels
(Pines 2014). The most common drug therappies for hypercholesterolemia are statins in
combination with diet modification. Side effects of statin use include muscle and liver damage,
impairment of cognitive function, and increased blood sugar (Dimmit 2015).
Lipid metabolism and inflammation are interconnected. Circulating cholesterol and lipids
are known to stimulate the inflammatory response (van Diepen 2013). Pro-inflammatory
cytokines also have a direct effect on lipid metabolism. As a result of this connection, lipidlowering drugs can also have anti-inflammatory effects. Statins, niacin, and fibrates decrease
inflammation by interacting directly with inflammatory pathways (van Diepen 2013). Nonsteroidal anti-inflammatory drugs (NSAIDs) are a major class of drugs used to treat pain and
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inflammation. Aspirin is an NSAID that decreases inflammation by reducing the synthesis of
prostaglandins. High-dose aspirin treatment also reduce lipid and cholesterol levels (van Diepen
2013). However, a study found that patients with cardiovascular disease who use the NSAIDs
diclofenac and rofecoxib are five times as likely to suffer a myocardial infarction than patients
with cardiovascular disease that don’t use those NSAIDs. (Schjerning 2014).
One mechanism of action to reduce inflammation is to target pro-inflammatory cytokines.
In low doses, a drug called methotrexate, serves as an anti-inflammatory drug by block the proinflammatory cytokine interlukin-1beta from binding to its receptor (van Diepen 2013).
Methotrexate has been shown to increase HDL levels in patients with rheumatoid arthritis (van
Diepen 2013). Possible side effects from methotrexate use include gastrointestinal bleeding and
edema. Tocilizumab, infliximab, and canakunimab also target pro-inflammatory cytokines.
These drugs decrease the levels of the pro-inflammatory cytokines tumor necrosis factor alpha,
interleukin 6 and interleukin-1beta respectively (van Diepen 2013). Specifically, these drugs
disrupt cytokine signaling by degrading the cytokine receptors. Anti-cytokine drugs can have
adverse gastrointestinal effects and interact with medicines such as birth control and blood
thinners.
As a result of the side effect of common drug therapies, research on natural products with
hypolipidemic properties is necessary. Historically, natural products have been the source of
many drugs and drug therapies. Between the years 1981 and 2010, 34% of drugs based on small
molecules came from natural product sources (Harvey 2015). Researchers have been analyzing
techniques that have utilized natural products for years, such as traditional Chinese medicine, in
an effort to find natural products that match their targets.
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Figure 5. Structures of lovastatin and compactin drug derivatives (Tobert 2003)..
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Natural product extracts usually contain multiple compounds, which can be obstacle or an
advantage. An array of compounds could mean that a single natural product could work on
multiple targets. On the other hand, inactive compounds present in larger amounts may block the
activity of less abundant active compounds. Complications with isolation and synthesizing of
natural products have caused a decline in natural product drug discovery over the past two
decades (Harvey 2015).
Table 1 shows 23 natural compounds and extracts that decreased or inhibited HMGR and
had additional hypolipidemic effects. The compounds and extracts are divided into in vivo and in
vitro studies. Compounds are further divided by the method of action: transcriptional or
enzymatic regulation.
One of the particularly interesting compounds is naringenin, a flavonoid from grapefruit,
exerts hypolipidemic effects in vitro. Rat hepatocytes treated with 200µM of naringenin had a
60% reduction in triglyceride production. Naringenin also increased LDLR expression and
decreased HMGR and HMG-CoA synthase (HMGCS) expression (Goldwasser 2010). HMGCS
is an enzyme involved in cholesterol biosynthesis. This compound has great medicinal potential
because it has shown anti-inflammatory and hypolipidemic effects in vivo and in vitro.
Additionally, the effect of naringenin on fatty acid oxidation and cholesterol biosynthesis
indicates that it may play an important role in the regulation of lipid metabolism (Goldwasser
2010).
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Korean soybean paste
Glycine soja
Nostoc commune
Rhizoma coptidis
Rosa damascena

Aglycone isoflavones
Inhibitory peptide GFPDGG
Lipid extract
M2/Columbamine
Roxyloside
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Celastrus paniculatus seed
Aconitum heterophyllum
Lemongrass oil
Grapefruit
Sophora japonica
Schizochytrium sp
Red koji
Plant-derived dietary flavanoid
Rhus verniciflua Stokes
Plants

Methanolic extract
Monoterpene geraniol
Naringenin
Sophoricoside
Sterol extracts
Red koji extract
Rutin
RVS glycoprotein
Tannic acid

Gingerol
Methanolic extract

Decrease HMGR mRNA

Allium sativum

β-amyrin acetate and β-amyrin
palmitate
Diallyldisulfide analogs
Symplocos racemosa Roxb
bark
Zingiber officinale

Citrus bergamia
Wrightia tomentosa leaves

Bergamot polyphenols

Ethanolic extract

Coptis chinensis

Berberine

Decreased HMGR mRNA levels

Inhibits HMGR

Decreased HMGR mRNA

Inhibits HMGR

Upregulates LDLR down regulates HMGR

Induces LDLR transcription, inhibits SREBP dependent
HMGR
Downregulates SREBP

Decreases translational efficacy of HMGR

Inhibits HMGR

Inhibits HMGR

Increased LDLR mRNA, decreased HMGR mRNA

Inhibited liver HMGR

Selective inhibition of HMGR
Inhibits HMGR by binding to active site

Schizochytrium

Decreased intestinal cholesterol absorption and HMGR
mRNA
Decreased hepatic cholesterol upregulated LDLR

Inhibits HMGR

Phosphorylates AMPK, AMPK inhibits HMGR in the liver

Inhibits SREBP-2 decreasing HMGR mRNA.

Binds competitively to HMGR

Inhibits HMGR

Inhibits HMGR

Method of Action

Algae powder

In vivo

Amyloid precursor protein

Source

Amyloid beta

In vitro

Compound/Extract

0.02% w/w

100mg/kg

200 µM

n/a

0.30 g/kg

10µM

100mg/kg
bw
200µM

400mg/kg

400mg/kg
bw
400mg/kg
bw
65 mg/kg

20mg/kg bw

10mg/kg bw

200mg/kg
bw
20 mg/day

10g/kg bw

0.12 mg/mL

15µM

100mg/L

IC50 1.5µM

30 µg/150µl

n/a

Dosage

Do 2011

Sun 2006

Cheng 2011

Wu 2003

Chen 2013

Wu 2014

Jayachandran
2015
Goldwasser 2010

Subash 2012

Patil 2010

Nammi 2010

Durkar 2014

Rai 2009

Maurya 2012

Mollace 2011

Chang 2012

Wu 2003

Kwon 2010

Cao 2013

Rasmussen 2008

Pak 2008

Sung 2012

Grimm 2007

Reference

Table 1. Natural Products with hypolipidemic properties.

Figure 6. Structure of naringenin (Goldwasser 2010).

Figure 7. Stuctures of active bergamot
ergamot flavonoids (Mollace 2011
2011).
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Another citrus plant with bioactivity is bergamot (Figure 7). Bergamot is known for its
high content and diversity of flavonoids. In a clinical study, polyphenol fractions of bergamot
juice were freeze-dried and turned into 500mg tablets. These tablets were given to an
experimental group of patients with hypercholesterolemia once a day. The control group of
hypercholesterolemic patients was given a daily 500mg placebo pill. After 30 days, patients who
took the bergamot pills had a 20% reduction in total cholesterol and LDL cholesterol (Mollace
2011). HPLC analysis of the bergamot fraction revealed five flavonoids that made up 26-28% of
the active fraction (Mollace 2011)
Spirulina platensis (also referred to as SP and Spirulina) is a prokaryotic blue green alga
also known as cyanobacteria. These organisms are photosynthetic but do not have plant cell
walls, nuclear membranes, or internal organelles, resembling bacterial cells (Singh 2007).
Spirulina was first isolated from a freshwater river in 1827 (Ciferri 1983). Indigenous
populations in Africa and Mexico are known to have cultivated Spirulina from lakes and
consumed the dried alga (Ciferri 1983). Spirulina has many bioactive components such as
chlorophylls, carotenoids, amino acids, minerals, phycocyanin and secondary metabolites (Singh
2007) (Figure 8a). Spirulina is known as a superfood because of the abundance of nutrients it
contains. The amounts of these various components depend on the environment in which the
Spirulina is grown (Singh 2007). Cyanobacteria are known to have a diverse range of biological
activity such as anti-malarial, anti-inflammatory, and anti-viral activity (Figure 8b).
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Figure 8. A) Composition of Spirulina platensis. B) known biological activity of cyanobacteria
(Singh 2007).
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In a previous studies done by Dr. Ji-Young Lee, the anti-inflammatory and hypolipidemic
properties of two edible genera of blue-green algae have been shown (Yang 2011). An extract of
the blue green algae Nostoc commune var. sphaeroides Kützing decreased the mRNA levels of
pro-inflammatory cytokines, HMGR and the LDL receptor (LDLR) in RAW macrophages and
HepG2 cells. In vivo studies of edible blue green algae with the C57BL/6J mice model of
hyperlipidemia have had similar results. Mice fed a high fat diet supplemented with Nostoc and
Spirulina for 4 weeks showed a change in the composition of intestinal bacteria and a decrease in
plasma triglyceride and cholesterol levels (Rasmussen 2009). These hypolipidemic effects are
attributed to an increased intestinal absorption of lipids and an increased fecal output (Ku 2013).
The long-term effects of Spirulina and Nostoc were studied in vivo by supplementing the diets of
mice with the BGA for six months. The mice from the experimental group showed no adverse
affects in comparison to the control group.
Although these studies have demonstrated the anti-inflammatory and hypolipidemic
properties of blue-green algae, the compounds responsible the bioactivity are unknown. The goal
of my project was to isolate the compound(s) responsible for the effects of Spirulina platensis.
Compound structures will be determined and these will be tested on biological assays.

Experimental
Fifty grams of dried Spirulina was obtained from Earthrise Nutritionals in Irvine, CA.
The dried algae was weighed and incubated overnight in 300mL of a 2:1 ratio of
dichloromethane (DCM) to methanol. After incubation, the alga and solvent were poured into a
funnel with coarse filter paper to separate the solvent from the alga. The alga was incubated 8-10
times until an exhaustive extraction was performed, resulting in 6.43 g of crude extract. The
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crude extract was rehydrated with hexanes, combined with silica (Pittsburg, PA) and passed
through a flash column. Solvents (500mL each) were passed through the column with added air
pressure according to the following ratio: A: 100% hexanes, B: 10% ethyl acetate
(EtOAc)/hexanes, C: 20% EtOAc/hexanes, D: 40% EtOAc/hexanes, E: 60% EtOAc/hexanes, F:
80% EtOAc/hexanes, G: 100% EtOAc, H: 25% MeOH/EtOAc, I: 100% MeOH, J: 100% DCM
and 100% MeOH.
GAPSP1 fractions A-J were analyzed using liquid chromatography mass spectroscopy
(LCMS) with Agilent ESI single quadrupole mass spectrometer (Santa Clara, CA) paired to
Agilent high performance liquid chromatography (HPLC) system with a G1311 quaternary
pump, G1322 degasser, and a G1315 diode array detector using an Eclipse XDB-C18 (4.6 × 150
mm, 5 µm) RP-HPLC column. Fractions that had shown activity in the previous study were also
tested on the Agilent HPLC system.
The bioactivity of SP was tested for HMG-CoA Reductase (HMGR) expression by
treating a HepG2 cell with the GAPSP1 fractions dissolved in dimethyl sulfoxide (DMSO) at a
concentration of 50 µg/mL of media. The HepG2 cells were incubated for 24 hours. Interleukin1β (IL-1b) expression was tested using RAW 264.7 mice macrophage bioassay. The fractions
were applied to at a concentration of 1 µg/mL. Before fractions were added, the macrophages
were treated with 100 ng/mL of lipopolysaccharide (LPS) to stimulate inflammation.
After analysis of the LCMS chromatograms, GAPSP1C was selected for further
fractionation by reverse phase solid phase extraction (SPE) on a DSC-18 500mg column using
60 mL of the following solvent systems: 1: 25% MeOH/ wawter (H2O) 2: 50% MeOH/H2O 3:
75% MeOH/H2O 4: 100% MeOH 5: 100% EtOAc.
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GAPSP1C fractions 1-5 were analyzed using LCMS. GAPSP1C4 was analyzed on HPLC
using 75% ACN and 70% ACN. GAPSP1C4A, GAPSP1C4B, GAPSP1C4W, GAPSP1C4A.E
were collected from GAPSP1C4 using HPLC at 60% ACN over 30 minutes (Figure 5).
GAPSP1C4B was 60% pure and 0.84 mg of the compound was isolated (Figure 6). GAPSP1C
and GAPSP1C4B proton NMR spectra were recorded on a Brüker Avance 500 MHz
spectrometer (500.13 MHz 1 H, 125.65 MHz 13C).

Results
In our previous study, the D fraction (40% EtOAc/hexanes) eluted during the normal
phase flash column chromatography of the initial crude SP extract, reduced IL-1B and HMGR
expression (Figure 9). Further HPLC isolation of the D fraction yielded compounds,
CSKSP1D1+2. CSKSP1D1+2 was isolated at 40% ACN and eluted at 8.5-9.5 minutes. The
isolated compounds also had a repressive effect on HMGR and IL-1B (Figure 10).
A similar peak to those found in the original compound was found in the C fraction.
GAPSP1C (Figure 15) eluted at 20% EtOAc/hexanes during normal phase flash column
chromatography of the crude SP extract. SPE of GAPSP1C yielded five fractions. Compound 1
and 2 were most prevalent in GAPSP1C4 but were also present in fractions GAPSP1C3, and
GAPSP1C5. HPLC isolation at 60% ACN for 30 minutes yielded GAPSP1C4A eluted at 17
minutes, GAPSP1C4B eluted at 26 minutes, GAPSP1C4A.E, and GAPSP1C4W (Figure 16).
GAPSP1C4B is 60% pure and contains a similar peak to that found in CSKSP1D1+2 (Figure
17). GAPSP1 fractions A, B, H, I, J repressed IL-1b expression in RAW 264.7 macrophages
(Figure 14). The fractions did not show significant activity against HMGR expression.
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Figure 9. Bioactivity of CSKSP fractions in A) HepG2 cells and B) RAW 264.7 macrophages
(Ku 2014).
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min

Figure 12. Proton NMR spectrum of CSKSPD1+2
CSKSPD1+2.
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Figure 14. IL-1b expression in RAW 264.7 macrophages after treatment with GAPSP1
fractions.
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Figure 15. A) HPLC chromatogram and B) mass trace of GAPSP1C.
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Figure 16. HPLC chromatogram of GAPSP1C4 at 60%ACN over 30 minutes. GAPSP1C4A,
GAPSP1C4B, GAPSP1C4A.E, GAPSP1C4W are highlighted.
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Figure 17. A) HPLC chromatogram and B) mass trace of GAPSP1C4B.
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1

Figure 18. Proton NMR of GAPSP1C4
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Discussion
Re-isolation of CSKSPD1+2 proved to be challenging because there was only a very
small amount of the compounds isolated. This limited the number of analyses that could be
performed. Also, large scale isolation of this compound was difficult because the active
compound was a very small portion of the crude Spirulina extract. Further analysis will be done
to determine if both compound 1 and 2 are active and if they act synergistically.
The original mass that was sought after in the GAPSP1 fractions was 369.1. This was the
mass of the most prevalent peak in the initial SP D fraction. Conversely, the isolated bioactive
compound, CSKSPD1+2, does not contain a peak with that mass. Future studies will pursue the
masses present in CSKSPD1+2.
GAPSP1C fraction was not active in the HMGR or IL-1B bioassays. This may be a result
of more abundant nuisance compounds overshadowing the anti-inflammatory or HMGRrepressing compounds that are present in smaller amounts. GAPSP1C4B will be tested in the
HMGR and IL-1B bioassays to analyze the bioactivity. However, because only 0.48 mg were
isolated, more of the compound will be necessary for structure determination.
CSKSPD1+2 activity against HMGR and IL-1B mRNA demonstrates that the
compounds are active transcriptionally. Future studies should analyze if the compounds also
inhibit the enzymatic activity of HMGR and/or prevent IL-1B from binding to its receptor.

Conclusion and Future Directions
The goal of this study was to isolate the compounds responsible for the hypolipidemic
and anti-inflammatory effects of the edible blue-green alga, Spirulina platensis. Initial
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fractionation of a crude Spirulina extract resulted in a bioactive D fraction which was further
fractionated into the bioactive compounds CSKSPD1+2. A second fractionation of a crude
Spirulina extract yielded a fraction, GAPSP1C that contained similar peaks to the original active
D fraction. The peak of interest was isolated in GAPSP1C4B, but not enough of the compound
was isolated to determine the chemical structure. Future studies will involve re-isolation of the
compound and comparison of the bioactivity of GAPSP1C4B to CSKSPD1+2. Additionally, the
synergistic activity of these two compounds and the other bioactive fractions will be analyzed.
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